Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06393712
Study type Interventional
Source Alnylam Pharmaceuticals
Contact Alnylam Clinical Trial Information Line
Phone 1-877-ALNYLAM
Email clinicaltrials@alnylam.com
Status Recruiting
Phase Phase 2
Start date May 2024
Completion date November 2029

See also
  Status Clinical Trial Phase
Completed NCT05486897 - Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy
Recruiting NCT03969732 - Multimodal Biomarkers for Diagnosis and Prognosis in CAA Phase 3
Completed NCT03542656 - Application of Amyloid PET in Cerebral Amyloid Angiopathy Phase 3
Recruiting NCT04604587 - MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA Phase 3
Completed NCT05565144 - Brain Hemorrhage and Functional Outcome in Stroke Patients With CAA Features on Pre-thrombolysis MRI Treated With Intravenous Thrombolysis (Thrombolysis in CAA) ( Thromb in CAA )
Active, not recruiting NCT03464344 - Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy. N/A
Completed NCT03824197 - Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD) N/A
Active, not recruiting NCT01856699 - Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy N/A
Recruiting NCT06128824 - High Frequency Imaging in Cerebral Amyloid Angiopathy
Completed NCT01821118 - Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy Phase 2
Not yet recruiting NCT06421532 - Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy Phase 2
Completed NCT05394636 - Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy
Recruiting NCT04204642 - SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)
Recruiting NCT05207475 - Safety and Efficacy of Remote Ischemic Conditioning on Cerebral Amyloid Angiopathy. (RIC-CAA) N/A
Recruiting NCT04757597 - Remote Ischemic Conditioning for Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage N/A
Not yet recruiting NCT02361411 - Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy N/A
Not yet recruiting NCT04654026 - the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA
Completed NCT05082194 - Balance Eyesight and Muscle Tension in the Cervical Spine in Cerebral Amyloid Angiopathy
Completed NCT04825808 - Detailed Clinical and MRI Characteristics in Primary Non-traumatic Convexity Subarachnoid Haemorrhage Elderly Patients.
Recruiting NCT05680389 - Antibiotics Against Amyloid Angiopathy Phase 1/Phase 2